|
| |
 |
OXFORD GENE TECHNOLOGY LAUNCHES CYTOSURE
PRODUCTS FOR THE CYTOGENETICS RESEARCH COMMUNITY |
Oxford, July 6th, 2007 - Oxford Gene Technology (OGT)
announces the launch of two array CGH (aCGH) products designed
exclusively for the cytogenetics research community. Branded under
the family name CytoSure™, Syndrome Plus and Chromosome X exon
specific arrays will debut at the European Cytogenetics Association
conference in Istanbul, 7th-10th July, 2007.
CytoSure Syndrome Plus is a 105,000 feature array covering the whole
genome, and includes probes designed to 85 constitutional syndromes
- including Cri du Chat, di Georges and Prader-Willi – and other
clinically relevant regions.
CytoSure ChrX array, a 44,000 feature array, has been developed in
collaboration with Dr Philippos Patsalis, Chief Executive and
Medical Director at the Cyprus Institute of Neurology and Genetics
in Nicosia, Cyprus. This unique design provides comprehensive
coverage of all relevant clinical areas across the X chromosome at
high resolution.
CytoSure arrays will be supplied with complimentary visualisation
software incorporating Copy Number Variation, gene and exon
annotation to ease data interpretation and build confidence.
Dr Mike Evans, CEO of Oxford Gene Technology said: “We are very
excited at OGT to be launching the CytoSure family – these are the
only oligonucleotide arrays designed exclusively for the
cytogenetics community and will enable cytogeneticists to achieve
accurate, high resolution analysis of chromosome copy number and
structural changes.”
- Ends-
For further information, please contact:
At Oxford Gene Technology:
Nicola Booton-Mander, Marketing Manager
Oxford Gene Technology
Begbroke Science Park
Sandy Lane Yarnton
Oxford OX5 1PF
T: +44 1865 856352
F: +44 1865 842116
E: products@ogt.co.uk
W: www.ogt.co.uk
Media Enquiries:
Annabel Entress, 0207 268 3002 /
a.entress@northbankcommunications.com
Sarah Jeffery, 0207 268 3002 /
s.jeffery@northbankcommunications.com
Notes to editors
About CytoSure™ arrays
The only oligonucleotide microarrays designed exclusively for the
cytogenetics research community providing:
§ enhanced detection of chromosomal abnormalities due to denser
coverage of clinically relevant regions using optimal length 60mer
oligonucleotides
§ complimentary visualisation software based on the latest build (36
NCBI) of the human genome incorporating Copy Number Variation, gene
and exon annotation to ease data interpretation and build
confidence.
About aCGH
In cytogenetics, aCGH is increasingly being used for the
identification of chromosomal aberrations associated with a number
of related genetic disorders at a higher resolution than
conventional non-array methods.
About Oxford Gene Technology
Founded in 1995 by the pioneer of Southern Blotting, Professor Sir
Edwin Southern, OGT operates out of Begbroke Business Park near
Oxford, with excellent access to a growing network of life science
companies
· OGT offers a comprehensive custom microarray consultancy service,
from experimental design through all stages to data analysis and
interpretation. It has a strong proven track record in providing
custom microarray service in a range of applications, and in May
2006 announced the launch of its first microarray product, an
Escherichia coli K12 ChIP on chip, the first ChIP microarray product
to be launched as part of OGT’s Prokaryotic Chip2 family
The key focus areas of OGT include:
1. Array-based application products and services for life science
research and molecular diagnostics. OGT’s flexible and
cost-effective, customised DNA microarray service covers a range of
applications, offering specialist support and assisting customers
with every aspect of their research, from initial consultation and
experimental design to probe selection, array design and fabrication
through to data analysis and interpretation.
2. Development of innovative platform products for clinical research
and diagnostics
3. Licensing. OGT operates an open licensing policy which has
successfully provided access for a number of companies to OGT's
fundamental intellectual property, particularly in the area of
microarrays
For further information on OGT visit
http://www.ogt.co.uk/
|
|
| |
|
